nach oben

Erschienen in:

04.09.2019 | Original Article

Real-world data on initial treatment strategies for older adult patients with endometrial cancer in Japan

verfasst von: Mayu Yunokawa, Shinsuke Sasada, Yae Takehara, Kenta Takahashi, Tatsunori Shimoi, Kan Yonemori, Mitsuya Ishikawa, Tomoyasu Kato, Kenji Tamura

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

Current strategies for the treatment of endometrial cancer in older adult patients require re-evaluation given the global trend in population aging, especially in Japan. We sought to evaluate initial treatment offered to older adult patients with endometrial cancer in Japan.

Methods

We retrospectively analyzed data on the standard treatment by age group in patients with endometrial cancer who underwent surgery between January 2005 and December 2013 at the National Cancer Center Hospital (Tokyo, Japan). Patients were stratified into four groups according to age: a younger group, aged 64 years or younger; older adult group 1, aged 65–69 years; older adult group 2, aged 70–74 years; and older adult group 3, aged ≥75 years.

Results

Among 551 patients with endometrial cancer diagnosed and treated at our hospital, data from 531 eligible patients were analyzed. The proportion of patients in the older adult groups 1 or 2 who received standard treatment was the same as in the younger group. However, significantly fewer patients in older adult group 3 received standard treatment compared with the younger group (26% vs. 71%, p = 0.0001). Furthermore, the proportion of patients in older adult group 3 who underwent standard surgery was significantly lower than that in the younger group (26% vs. 72%, p = 0.0001).

Conclusions

The results indicate that age 75 years and older might represent a cutoff for the development of age-based treatment strategies for endometrial cancer. This information could be used to determine the upper age limit for participation in clinical trials in Japan.

Saito T, Takahashi F, Katabuchi H, Committee on Gynecologic Oncology of the Japan Society of O, Gynecology (2017) Annual report of the committee on gynecologic oncology, Japan society of obstetrics and gynecology: patient annual report for 2014 and treatment annual report for 2009. J Obstet Gynaecol Res 43(11):1667–1677. https://doi.org/10.1111/jog.13450 CrossRefPubMed

United States census bureau. International data base. http://www.census.gov/population/international/data/idb/informationGateway.php. Accessed 31 Dec 2018

World Health Organization. http://www.who.int/healthinfo/survey/ageingdefnolder/en/. Accessed 31 Dec 2018

Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT (2004) Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22(11):2159–2166. https://doi.org/10.1200/JCO.2004.07.184 CrossRefPubMed

Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, Thigpen JT, Benda JA, Gynecologic Oncology Group S (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24(1):36–44. https://doi.org/10.1200/JCO.2004.00.7617 CrossRefPubMed

Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G, Colombo A, Fossati R (2006) Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 95(3):266–271. https://doi.org/10.1038/sj.bjc.6603279 CrossRefPubMedPubMedCentral

Miller D et al (2012) Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 125:771–773CrossRef

Talarico L, Chen G, Pazdur R (2004) Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 22(22):4626–4631. https://doi.org/10.1200/JCO.2004.02.175 CrossRefPubMed

Creasman W (2009) Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet 105(2):109. https://doi.org/10.1016/j.ijgo.2009.02.010 CrossRefPubMed

10.

Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15(1):10–17CrossRefPubMed

11.

Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, Falandry C, Artz A, Brain E, Colloca G, Flamaing J, Karnakis T, Kenis C, Audisio RA, Mohile S, Repetto L, Van Leeuwen B, Milisen K, Hurria A (2014) International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 32(24):2595–2603. https://doi.org/10.1200/JCO.2013.54.8347 CrossRefPubMedPubMedCentral

12.

Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, Lichtman S, Mor V, Monfardini S, Repetto L, Sorbye L, Topinkova E, Task Force on CGAotISoGO (2005) Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol/Hematol 55(3):241–252. https://doi.org/10.1016/j.critrevonc.2005.06.003 CrossRef

13.

Mathoulin-Pelissier S, Bellera C, Rainfray M, Soubeyran P (2013) Screening methods for geriatric frailty. Lancet Oncol 14(1):e1–e2. https://doi.org/10.1016/S1470-2045(12)70554-5 CrossRefPubMed

14.

Decoster L, Van Puyvelde K, Mohile S, Wedding U, Basso U, Colloca G, Rostoft S, Overcash J, Wildiers H, Steer C, Kimmick G, Kanesvaran R, Luciani A, Terret C, Hurria A, Kenis C, Audisio R, Extermann M (2015) Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendationsdagger. Ann Oncol 26(2):288–300. https://doi.org/10.1093/annonc/mdu210 CrossRefPubMed

15.

Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, Sessa C, Group EGW (2013) Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi33–vi38. https://doi.org/10.1093/annonc/mdt353 CrossRefPubMed

16.

Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Ledermann J, Marth C, Nout R, Querleu D, Mirza, Sessa C, Group E-E-EECCW (2016) ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol 27(1):16–41. https://doi.org/10.1093/annonc/mdv484 CrossRefPubMed

17.

Nagase S, Katabuchi H, Hiura M, Sakuragi N, Aoki Y, Kigawa J, Saito T, Hachisuga T, Ito K, Uno T, Katsumata N, Komiyama S, Susumu N, Emoto M, Kobayashi H, Metoki H, Konishi I, Ochiai K, Mikami M, Sugiyama T, Mukai M, Sagae S, Hoshiai H, Aoki D, Ohmichi M, Yoshikawa H, Iwasaka T, Udagawa Y, Yaegashi N, Japan Society of Gynecologic O (2010) Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition. Int J Clin Oncol 15(6):531–542. https://doi.org/10.1007/s10147-010-0138-6 CrossRefPubMed

18.

Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, Angioli R, Tateo S, Mangili G, Katsaros D, Garozzo G, Campagnutta E, Donadello N, Greggi S, Melpignano M, Raspagliesi F, Ragni N, Cormio G, Grassi R, Franchi M, Giannarelli D, Fossati R, Torri V, Amoroso M, Croce C, Mangioni C (2008) Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100(23):1707–1716. https://doi.org/10.1093/jnci/djn397 CrossRefPubMed

19.

Group As, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK (2009) Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373(9658):125–136. https://doi.org/10.1016/S0140-6736(08)61766-3 CrossRef

20.

Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N (2010) Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 375(9721):1165–1172. https://doi.org/10.1016/S0140-6736(09)62002-X CrossRefPubMed

21.

Rauh-Hain JA, Melamed A, Schaps D, Bregar AJ, Spencer R, Schorge JO, Rice LW, Del Carmen MG (2018) Racial and ethnic disparities over time in the treatment and mortality of women with gynecological malignancies. Gynecol Oncol 149(1):4–11. https://doi.org/10.1016/j.ygyno.2017.12.006 CrossRefPubMed

22.

Lewin SN, Herzog TJ, Barrena Medel NI, Deutsch I, Burke WM, Sun X, Wright JD (2010) Comparative performance of the 2009 international federation of gynecology and obstetrics’ staging system for uterine corpus cancer. Obstet Gynecol 116(5):1141–1149. https://doi.org/10.1097/AOG.0b013e3181f39849 CrossRefPubMed

23.

Ward KK, Shah NR, Saenz CC, McHale MT, Alvarez EA, Plaxe SC (2012) Cardiovascular disease is the leading cause of death among endometrial cancer patients. Gynecol Oncol 126(2):176–179. https://doi.org/10.1016/j.ygyno.2012.04.013 CrossRefPubMed

24.

Felix AS, Bower JK, Pfeiffer RM, Raman SV, Cohn DE, Sherman ME (2017) High cardiovascular disease mortality after endometrial cancer diagnosis: results from the Surveillance, Epidemiology, and End Results (SEER) Database. Int J Cancer 140(3):555–564. https://doi.org/10.1002/ijc.30470 CrossRefPubMed

25.

Sud S, Holmes J, Eblan M, Chen R, Jones E (2018) Clinical characteristics associated with racial disparities in endometrial cancer outcomes: a surveillance, epidemiology and end results analysis. Gynecol Oncol 148(2):349–356. https://doi.org/10.1016/j.ygyno.2017.12.021 CrossRefPubMed

26.

Tarney CM, Tian C, Wang G, Dubil EA, Bateman NW, Chan JK, Elshaikh MA, Cote ML, Schildkraut JM, Shriver CD, Conrads TP, Hamilton CA, Maxwell GL, Darcy KM (2018) Impact of age at diagnosis on racial disparities in endometrial cancer patients. Gynecol Oncol 149(1):12–21. https://doi.org/10.1016/j.ygyno.2017.07.145 CrossRefPubMed

27.

Lee YY, Choi CH, Kim CJ, Song TJ, Kim MK, Kim TJ, Lee JW, Kim BG, Lee JH, Bae DS (2010) Glucose as a prognostic factor in non-diabetic women with locally advanced cervical cancer (IIB-IVA). Gynecol Oncol 116(3):459–463. https://doi.org/10.1016/j.ygyno.2009.11.016 CrossRefPubMed

28.

Modh A, Ghanem AI, Burmeister C, Rasool N, Elshaikh MA (2016) Trends in the utilization of adjuvant vaginal brachytherapy in women with early-stage endometrial carcinoma: results of an updated period analysis of SEER data. Brachytherapy 15(5):554–561. https://doi.org/10.1016/j.brachy.2016.06.012 CrossRefPubMed

Titel: Real-world data on initial treatment strategies for older adult patients with endometrial cancer in Japan
verfasst von: Mayu Yunokawa
Shinsuke Sasada
Yae Takehara
Kenta Takahashi
Tatsunori Shimoi
Kan Yonemori
Mitsuya Ishikawa
Tomoyasu Kato
Kenji Tamura
Publikationsdatum: 04.09.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 5/2019
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-019-03938-8

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Real-world data on initial treatment strategies for older adult patients with endometrial cancer in Japan

Abstract

Objective

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Population pharmacokinetics and exposure–overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer

Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases

The thioredoxin system and cancer therapy: a review

Prodrugs as drug delivery system in oncology

Population pharmacokinetics of siltuximab: impact of disease state

Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie